title: Comparison of Telbivudine and Entecavir Therapy on Nephritic Function and Drug Resistance in Patients with Hepatitis B Virus-Related Compensated Cirrhosis.
abstract: BACKGROUND
  To compare the impact of telbivudine (LDT) and entecavir (ETV) administration on nephritic function.
  
  
  METHODS
  One hundred thirty patients diagnosed with hepatitis B virus (HBV)-related compensated cirrhosis were randomly divided into LDT (600 mg/d) or ETV (0.5 mg/d) groups.
  
  
  RESULTS
  The drug resistance rate was higher following LDT treatment compared to ETV treatment (16.9% vs. 1.5%, P=0.0006). The mean creatinine level decreased compared to baseline in the LDT group (0.81 vs. 0.94 mg/dl, P=0.000). The change in median glomerular filtration rate (eGFR) compared to baseline in the LTD and ETV groups was 22.3 and -3.3, respectively, at 2 years (P=0.000). In patients with mild nephritic injury (eGFR< 90 ml/min/1.73m2), the median eGFR increased by 28.0 ml/min/1.73m2 in the LDT group and decreased by 4.3 ml/min/1.73m2 in the ETV group (p=0.000). The eGFR in 88.5% of patients (23/26) from the LDT group increased > 90 ml/min/1.73m2. The percentage of patients with an eGFR > 90 ml/min/1.73m2 increased from 60.0% to 92.3% in the LDT group and from 64.6% to 69.2% in the ETV group.
  
  
  CONCLUSIONS
  In patients with HBV-related compensated cirrhosis, LDT treatment was more effective in protecting nephritic function and was associated with a higher drug resistance rate, but did not contribute to a better outcome compared with ETV treatment.
authors.affiliation: Department of Hepatology, ShaoXing Municipal Hospital, ShaoXing, Zhejiang Province, China.
authors.forename: Huajiang
authors.initials: H
authors.lastname: Shen
authors.forename: Feng
authors.initials: F
authors.lastname: Ding
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Wang
authors.forename: Fang
authors.initials: F
authors.lastname: Sun
authors.forename: Yafeng
authors.initials: Y
authors.lastname: Yu
authors.forename: Jiankang
authors.initials: J
authors.lastname: Zhou
authors.forename: Wenfang
authors.initials: W
authors.lastname: Xu
authors.forename: Jianchao
authors.initials: J
authors.lastname: Ni
authors.forename: Jiangang
authors.initials: J
authors.lastname: Wang
authors.forename: Yida
authors.initials: Y
authors.lastname: Yang
mesh_terms: D003404:Creatinine / Q000097:blood; D004279:DNA, Viral / Q000235:genetics; D024882:Drug Resistance, Viral / Q000187:drug effects; D005260:Female; D005919:Glomerular Filtration Rate; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D007677:Kidney Function Tests; D008103:Liver Cirrhosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D000077712:Telbivudine; D013936:Thymidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D004279:DNA, Viral; D000077712:Telbivudine; C413685:entecavir; D006147:Guanine; D003404:Creatinine; D013936:Thymidine